

Galleon Pharmaceuticals Names Lynne Brookes Senior Vice President and Chief Business Officer

Horsham, PA – December 1, 2011 – Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing-control disorders, today announced the appointment of Lynne M. Brookes as senior vice president and chief business officer. She joins Galleon from Cephalon, Inc. where she held a variety of product management, marketing and business development positions and was most recently vice president of business development. She joined Cephalon in 1995 as a product manager and was responsible for commercializing many of Cephalon's pharmaceutical products including PROVIGIL, the company's most successful drug.

Brookes stated: "I am excited to join the Galleon team and develop the commercial strategy for their portfolio of compounds. I look forward to applying my previous marketing experience with sleep apnea and opioid analgesics to Galleon's emerging pipeline of innovative product candidates that address the needs of patients in under-served markets."

James C. Mannion, Ph.D., Galleon's president, chief executive officer and founder, stated: "Lynne is uniquely well-qualified to serve as our chief business officer because of her experience launching and managing very successful pharmaceutical products in markets that include many breathing-control-disorder patients. She provides a strong commercial perspective to compliment our established drug-discovery and clinical-development teams."

Previously, Brookes was senior associate, endocrine products, at Genentech and a sales representative and medicinal chemist at Merck & Co. She received a Bachelor of Science degree in chemistry from Yale University and a Master of Business Administration degree from the Wharton School of the University of Pennsylvania.

About Galleon Pharmaceuticals

Galleon is the first pharmaceutical company to focus on the medical treatment of breathing-control disorders associated with surgical and procedural sedation, chronic pain management and sleep apnea. The company's product pipeline reflects recent advances in neurobiology, molecular biology and respiratory medicine which have enabled the development of a unique drug-discovery platform and promising drug candidates that are now undergoing clinical trials. Galleon scientists apply sophisticated pharmacology, medicinal chemistry and drug-discovery tools to identify potential medical treatments for acute and chronic breathing-control conditions. This approach is unique among pharmaceutical companies and enables the rapid evaluation of multiple variables to establish a comprehensive profile of breathing-control activity. For more information, please visit www.galleonpharma.com.